CMR Surgical's alliance with Stryker

Stryker puts about $400m into CMR, takes an exclusive option to buy it, and will sell Versius in the US - its way into a soft-tissue market Intuitive has led for two decades.

AI analysis by Aleth · primary release

Summary

Stryker (NYSE: SYK) is to make an approximately $400 million (£300 million) preferred equity investment in CMR, with an exclusive option to acquire all of CMR later, and becomes exclusive US sales agent for Versius. CMR continues to lead development, and selling outside the US. The deal is subject to regulatory approvals and has yet to close.

For CMR it is the largest raise since the 2021 Series D, more than three times the £87.4m it held at the end of 2025, and it hands the US launch to a sales force already in American operating theatres. CMR had hired a US president in August 2025 and said in December 2025 it was "on track to begin commercialisation in 2026".

For Stryker it is the entry it has long held back from. It leads orthopaedic robotics with Mako but has had no soft-tissue robot. In the words of Andy Pierce, its Group President, MedSurg and Neurotechnology, who joins CMR's board: "We have evaluated the segment carefully for years, and this alliance represents a thoughtful and disciplined entry".

The terms

Term                                                    As stated
Investment                  About $400m (£300m), preferred equity
Use            Innovation and global commercialisation of Versius
Option            Exclusive, to acquire 100% of CMR in the future
United States                       Stryker exclusive sales agent
Elsewhere       CMR leads development, and selling outside the US
Conditions     Regulatory approvals, customary closing conditions

No valuation, option price or exercise window was given. The last valuation CMR stated was $3bn, at the Series D in June 2021.

Stryker’s entry into robotic surgery

CMR's own accounts describe robotic-assisted surgery as "dominated by a single participant", with procedures growing about 20% a year. CMR does not name it, but it is Intuitive, and the gap in scale is wide:

                                 Intuitive                   CMR
Installed base        11,710 (30 Jun 2026)   c.227 (31 Dec 2025)
Placed                468 in Q2 2026 alone          48 in FY2025
Procedures      c.889,000 in Q2 2026, +15%        13,253 in 2025
Revenue                 $2.89bn in Q2 2026      £51.7m in FY2025
US clearances             Many specialties  Cholecystectomy only

Intuitive's revenue covers all its products. Figures from its Q2 2026 results and 10-Q, July 2026; CMR's from its FY2025 accounts and its 510(k) release of December 2025.

Da Vinci performs more procedures in a week than Versius did in all of 2025. Outside the US CMR ranks itself second, calling Versius in April 2026 "the second most utilized surgical robotic system globally outside of the United States".

Intuitive's other challengers are moving too. Medtronic's Hugo was cleared in the US for urology in December 2025, and J&J's Ottava received FDA De Novo authorisation in July 2026. Versius was authorised in the US before either, in October 2024, and now has Stryker's operating-room franchise behind it. Stryker says it will sell Versius to hospitals and to ambulatory surgery centres (ASCs), the cheaper outpatient units where US surgery is moving. Versius is modular and moves between operating rooms, which may suit those centres better than hospitals already built around da Vinci. J.P. Morgan’s Robbie Marcus doubts it will dent Intuitive: “we don’t think Stryker/CMR will be effective at displacing da Vinci in the [U.S.] any time soon”, he wrote, quoted by MedTech Dive. He expects Medtronic and J&J to be impacted more.

Read-through and what to watch

Once closed, the money settles CMR's funding for some years. At last year's average burn of about £5m a month, £300m covers several years, and Stryker, as sales agent, takes on the US selling. CMR has said it aims to make "progress toward profitability by 2027".

The US case rests on indications. Versius is cleared in the US for one procedure. A 510(k) for benign gynecology was submitted in April and was still pending in July. Gynecologic procedures are, CMR says, "a large proportion of all Versius cases recorded globally". Stryker's sales force needs that broader label to sell into.

The option makes Stryker the likely owner. It is exclusive and covers the whole company, which makes a rival bid unlikely. What existing holders receive depends on terms not yet disclosed, and on where Stryker's preferred shares rank against theirs.

Key follow-ups:

Closing, and any conditions the regulators attach.
The gynecology 510(k), the second US indication.
Where Stryker places Versius first: ASCs, or hospitals in direct contest with da Vinci.
Versius 2, whose release CMR's accounts say is on "an increased timeline", and whether the new money changes that.
The option's terms, if either party discloses them, and whether Stryker exercises.